🕒 Last update: loading…

Stock Oncotelic Therapeutics, Inc. OTLC

Oncotelic Therapeutics, Inc. — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ✅ Debt passed
  • ✅ P/E passed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: 112.50%

Price change 2019 → 2020: 29.41%

Price change 2020 → 2021: -22.73%

Price change 2021 → 2022: -73.53%

Price change 2022 → 2023: -15.00%

Price change 2023 → 2024: -8.50%

Price change 2024 → 2025: 124.00%

Price change 2025 → 2026: -50.57%

Price change 2026 (year to date): -50.19%

Financial growth

Revenue CAGR (8 years): N/A

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.06

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 0.03

P/E < 25.0 (maximum threshold).

Correction (6 months)

Current correction: 48.33% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Oncotelic Therapeutics, Inc.–0.05–🔒
Spineway S.A.–0.07+9.3 %–
WORK Medical Technology Group Ltd.–0.35−28.4 %–
CompuMed, Inc.–0.23+10.2 %–
Daré Bioscience, Inc.–0.93+9.1 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Oncotelic Therapeutics, Inc. over the latest fiscal years.

Revenue
70,000 USD
fiscal year 2023
Net income
-7.9 m USD
fiscal year 2023
Net margin
-11,290.1 %
fiscal year 2023
Average annual growth
-5.9 %
Revenue growth over 5 years
Market cap
4.6 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
201395,000-8.3 m-8,712.6 %n/a
201495,000-12.6 m-13,312.6 %0.0 %
2017-100-13.8 m13,812,000.0 %-100.1 %
2018-100-2.7 m2,737,000.0 %n/a
20201.7 m-11.5 m-660.6 %n/a
202370,000-7.9 m-11,290.1 %-96.0 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Oncotelic Therapeutics, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-0.05
risk zone (below 1.81)
Piotroski Score
3 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
45,802.39 x
high debt
Fiscal year20212022202320242025
Cash and investments568,769241,452170,40586,12888,857
Total Debt9.0 m11.3 m12.6 m13.1 m13.9 m
Net Debt8.4 m11.0 m12.4 m13.0 m13.8 m
Equity8.0 m19.4 m12.1 m8.3 mn/a
Total assets23.6 m36.1 m30.0 m26.7 mn/a
Operating cash flow-4.4 m-1.5 m-1.3 m-740,267-1.4 m
Investments (capex)00330
Free cash-flow-4.4 m-1.5 m-1.3 m-740,267-1.4 m
Share buybacks00125,00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Return on Equity (ROE)0.0 %
Return on Invested Capital (ROIC)-0.0 %
Debt / equity0.06 x
Current ratio0.07 x
Interest coverage-4.77 x

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

Oncotelic Therapeutics, Inc. compared with its sector on the same exchange and with its main competitors.

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Oncotelic Therapeutics, Inc.4.6 mn/a0.0 %
Amplia Therapeutics Limited INNMF27.7 mn/a-173.7 %
PsyBio Therapeutics Corp. PSYBF1,275n/an/a
Arch Biopartners Inc. ACHFF44.8 mn/a0.0 %
Covalon Technologies Ltd. CVALF81.2 m25.96.3 %
Helix BioPharma Corp. HBPCF58.8 mn/a0.0 %
Cannabix Technologies Inc. BLOZF31.5 mn/a0.0 %
ZIVO Bioscience, Inc. ZIVO22.4 mn/a-8,311.1 %

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Dividends and earnings

Oncotelic Therapeutics, Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
13/08/20260.00-0.02n/a
14/05/2026-0.00-0.02n/a
15/04/20260.59-0.02n/a

Stock splits

DateOperation
28/12/2012reverse split: 1 share for 12
23/02/2011reverse split: 1 share for 20

Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Oncotelic Therapeutics, Inc.

Free float
51.6 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
OTC (hors cote)
IPO: 26/08/1993
ISIN code
US6283411097
Workforce
26
full-time employees
Chief executive
Vuong Trieu

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Oncotelic Therapeutics, Inc.

What is the Oncotelic Therapeutics, Inc. share price?

Latest recorded price: 0.0100 USD on 13/11/2026, for a market cap of 4.6 m USD.

What is the revenue of Oncotelic Therapeutics, Inc.?

70,000 USD for fiscal year 2023, with net income of -7.9 m USD (net margin -11,290.1 %).

Is Oncotelic Therapeutics, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US6283411097).

How many employees does Oncotelic Therapeutics, Inc. have?

26 full-time employees according to the latest published profile.

Who runs Oncotelic Therapeutics, Inc.?

Vuong Trieu is the company's chief executive.

07

Similar stocks